Showing results (121-130 of 187) with videos related to

Sort By:
Pageof 19
The Journal of Rheumatology|December 17, 2010
Phenotypic changes of lymphocytes in patients with systemic lupus erythematosus who are in longterm remission after B cell depletion therapy with rituximabShigeru Iwata, Kazuyoshi Saito, Mikiko Tokunaga, et al.
Rheumatology (Oxford, England)|April 4, 2017
Differential effects of biological DMARDs on peripheral immune cell phenotypes in patients with rheumatoid arthritisShingo Nakayamada, Satoshi Kubo, Maiko Yoshikawa, et al.
Annals of the Rheumatic Diseases|November 30, 2013
Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR studyYoshiya Tanaka, Shintaro Hirata, Satoshi Kubo, et al.
Arthritis Research & Therapy|June 29, 2022
Safety and effectiveness of mepolizumab therapy in remission induction therapy for eosinophilic granulomatosis with polyangiitis: a retrospective studyMasanobu Ueno, Ippei Miyagawa, Takafumi Aritomi, et al.
RMD Open|May 15, 2023
Sustained remission following the discontinuation of tofacitinib in patients with rheumatoid arthritis (XANADU study): an open-label randomised studySatoshi Kubo, Yusuke Miyazaki, Koichi Amano, et al.
Arthritis Research & Therapy|April 16, 2022
Impact of serum interleukin-22 as a biomarker for the differential use of molecular targeted drugs in psoriatic arthritis: a retrospective studyIppei Miyagawa, Shingo Nakayamada, Masanobu Ueno, et al.
Analytical Chemistry|December 17, 2016
One-Shot In Vitro Evolution Generated an Antibody Fragment for Testing Urinary Cotinine with More Than 40-Fold Enhanced AffinityHiroyuki Oyama, Izumi Morita, Yuki Kiguchi, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 13, 2017
Peripheral Immunophenotyping Identifies Three Subgroups Based on T Cell Heterogeneity in Lupus PatientsSatoshi Kubo, Shingo Nakayamada, Maiko Yoshikawa, et al.
European Journal of Pharmacology|March 29, 2018
Generation and characterization of a potent fully human monoclonal antibody against the interleukin-23 receptorHaruna Sasaki-Iwaoka, Makoto Ohori, Akira Imasato, et al.
Modern Rheumatology|February 14, 2016
Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practiceShintaro Hirata, Wanying Li, Satoshi Kubo, et al.
Pageof 19